Jay Olivet, Matthew L Brown, Megan Amerson-Brown, W Seth Edwards, Robert A Oster, Joshua Stripling
{"title":"Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia.","authors":"Jay Olivet, Matthew L Brown, Megan Amerson-Brown, W Seth Edwards, Robert A Oster, Joshua Stripling","doi":"10.1017/ash.2026.10749","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rapid molecular blood culture identification (BCID) enables earlier pathogen identification and targeted antibiotic therapy compared with traditional culture-based methods. Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) bacteremia is optimally treated with anti-staphylococcal β-lactam antibiotics; however, delays in bacterial identification frequently result in prolonged empiric anti-methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) therapy. Data evaluating the clinical impact of early MSSA identification remain limited.</p><p><strong>Methods: </strong>This retrospective, single-center, quasi-experimental program evaluation included adult patients with monomicrobial MSSA bacteremia. Patients were grouped based on identification by BCID or conventional culture-based methods. Automatic Infectious Diseases consultation was performed for all patients. The primary outcome was a desirability of outcome ranking incorporating treatment success, acute kidney injury (AKI), and inpatient mortality. Secondary outcomes included time-to-optimal therapy, duration of bacteremia, treatment success, and hospital length of stay.</p><p><strong>Results: </strong>A total of 300 patients were included (150 per cohort). BCID use was associated with earlier MSSA identification (0.8 vs 2.1 days; <i>P</i> < .001) and earlier initiation of targeted β-lactam therapy (1.9 vs 3.8 days; <i>P</i> < .001). The probability of a more desirable outcome with BCID was 58.5% (95% CI: 52.5% to 64.3%), and more individuals achieved the most desirable outcome (62.0% vs 46.0%; <i>P</i> = .005). AKI occurred less frequently in the BCID group (23.5% vs 44.2%; <i>P</i> < .001).</p><p><strong>Conclusions: </strong>Incorporation of rapid BCID into an established automatic Infectious Diseases consultation program improved outcomes in MSSA bacteremia by facilitating earlier β-lactam therapy and reducing nephrotoxicity. Antimicrobial stewardship programs should prioritize rapid diagnostics to optimize MSSA management.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"6 1","pages":"e182"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312251/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial stewardship & healthcare epidemiology : ASHE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/ash.2026.10749","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Rapid molecular blood culture identification (BCID) enables earlier pathogen identification and targeted antibiotic therapy compared with traditional culture-based methods. Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is optimally treated with anti-staphylococcal β-lactam antibiotics; however, delays in bacterial identification frequently result in prolonged empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy. Data evaluating the clinical impact of early MSSA identification remain limited.
Methods: This retrospective, single-center, quasi-experimental program evaluation included adult patients with monomicrobial MSSA bacteremia. Patients were grouped based on identification by BCID or conventional culture-based methods. Automatic Infectious Diseases consultation was performed for all patients. The primary outcome was a desirability of outcome ranking incorporating treatment success, acute kidney injury (AKI), and inpatient mortality. Secondary outcomes included time-to-optimal therapy, duration of bacteremia, treatment success, and hospital length of stay.
Results: A total of 300 patients were included (150 per cohort). BCID use was associated with earlier MSSA identification (0.8 vs 2.1 days; P < .001) and earlier initiation of targeted β-lactam therapy (1.9 vs 3.8 days; P < .001). The probability of a more desirable outcome with BCID was 58.5% (95% CI: 52.5% to 64.3%), and more individuals achieved the most desirable outcome (62.0% vs 46.0%; P = .005). AKI occurred less frequently in the BCID group (23.5% vs 44.2%; P < .001).
Conclusions: Incorporation of rapid BCID into an established automatic Infectious Diseases consultation program improved outcomes in MSSA bacteremia by facilitating earlier β-lactam therapy and reducing nephrotoxicity. Antimicrobial stewardship programs should prioritize rapid diagnostics to optimize MSSA management.
背景:与传统的基于培养的方法相比,快速分子血培养鉴定(BCID)能够更早地识别病原体和靶向抗生素治疗。甲氧西林敏感金黄色葡萄球菌(MSSA)菌血症的最佳治疗方法是抗葡萄球菌β-内酰胺抗生素;然而,细菌鉴定的延误常常导致经验性抗甲氧西林金黄色葡萄球菌(MRSA)治疗的延长。评估早期MSSA识别的临床影响的数据仍然有限。方法:回顾性、单中心、准实验方案评估纳入单微生物MSSA菌血症的成年患者。采用BCID或常规培养方法对患者进行分组。所有患者均进行传染病自动会诊。主要结局是纳入治疗成功、急性肾损伤(AKI)和住院病人死亡率的结局排序的可取性。次要结局包括最佳治疗时间、菌血症持续时间、治疗成功和住院时间。结果:共纳入300例患者(每个队列150例)。BCID的使用与早期发现MSSA (0.8 vs 2.1天,P < 0.001)和早期开始靶向β-内酰胺治疗(1.9 vs 3.8天,P < 0.001)相关。BCID获得更理想结果的概率为58.5% (95% CI: 52.5%至64.3%),获得最理想结果的个体更多(62.0% vs 46.0%; P = 0.005)。BCID组AKI发生率较低(23.5% vs 44.2%; P < 0.001)。结论:将快速BCID纳入已建立的传染病自动会诊计划,通过促进早期β-内酰胺治疗和减少肾毒性,改善了MSSA菌血症的预后。抗菌药物管理计划应优先考虑快速诊断以优化MSSA管理。